Hypera signed a contract with Sanofi to acquire 12 over-the-counter drug brands in Brazil, Mexico and Colombia for US$190.3 million. Among the products acquired are the analgesic AAS, the herbal medicine Naturetti and the antiseptic Cepacol, in addition to the prescription medications Buclina, to stimulate appetite, and Hidantal, indicated for the treatment of epilepsy, among others. Brazil represented approximately 67% of the net revenue of this portfolio in 2020.
“The transaction is in line with the company’s strategy of strengthening its presence in the Brazilian market through products with high growth potential. With the conclusion of this acquisition, Hypera Pharma will increase its performance in the categories of Consumer Health and Prescription Products, with emphasis on the central nervous system and the gastrointestinal system”, highlighted the company in a statement.
Hypera Pharma and Sanofi will sign a manufacturing and supply agreement in connection with the transaction, whereby Sanofi will continue to supply products to the company for a period of up to 3 years. The transaction is also subject to certain conditions precedent, including approval by the competent antitrust authorities.
+ Learn about the effectiveness of each vaccine against Covid-19